Condensed Consolidated Statements of Stockholders' Deficiency - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)			154,840,902
Beginning Balance	$ (797,125)	$ (830,912)	$ (807,877)	$ (841,553)
Net income	52,699	38,856	125,529	110,551
Total other comprehensive income	178	303	548	855
Dividends on common stock	(31,755)	(31,739)	(95,274)	(95,265)
Restricted stock grants			0	0
Withholding of shares as payment of payroll tax liabilities in connection with restricted stock vesting	(25)	(1,111)	(3,177)	(2,668)
Withholding of shares as payment of payroll tax liabilities in connection with exercise of stock options			(12,633)
Exercise of stock options			12,105
Stock-based compensation	$ 2,673	1,558	$ 7,424	6,275
Reallocation of distribution of Douglas Elliman				0
Other		(265)		(1,505)
Ending Balance (in shares)	155,933,020		155,933,020
Ending Balance	$ (773,355)	$ (823,310)	$ (773,355)	$ (823,310)
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)	155,934,987	154,896,129	154,840,902	153,959,427
Beginning Balance	$ 15,593	$ 15,490	$ 15,484	$ 15,396
Restricted stock grants (in shares)			1,290,000	1,070,000
Restricted stock grants			$ 129	$ 107
Withholding of shares as payment of payroll tax liabilities in connection with restricted stock vesting (in shares)	(1,967)	(100,227)	(240,948)	(233,525)
Withholding of shares as payment of payroll tax liabilities in connection with restricted stock vesting		$ (10)	$ (25)	$ (23)
Withholding of shares as payment of payroll tax liabilities in connection with exercise of stock options (in shares)			(1,012,249)
Withholding of shares as payment of payroll tax liabilities in connection with exercise of stock options			$ (101)
Exercise of stock options (in shares)			1,055,315
Exercise of stock options			$ 106
Ending Balance (in shares)	155,933,020	154,795,902	155,933,020	154,795,902
Ending Balance	$ 15,593	$ 15,480	$ 15,593	$ 15,480
Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	6,054	3,066	5,092	11,172
Restricted stock grants			(129)	(107)
Withholding of shares as payment of payroll tax liabilities in connection with restricted stock vesting	(25)	(1,101)	(3,152)	(2,645)
Withholding of shares as payment of payroll tax liabilities in connection with exercise of stock options			(12,532)
Exercise of stock options			11,999
Stock-based compensation	2,673	1,558	7,424	6,275
Reallocation of distribution of Douglas Elliman				(11,172)
Ending Balance	8,702	3,523	8,702	3,523
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(803,069)	(834,297)	(812,380)	(852,398)
Net income	52,699	38,856	125,529	110,551
Dividends on common stock	(31,755)	(31,739)	(95,274)	(95,265)
Reallocation of distribution of Douglas Elliman				11,172
Other		(265)		(1,505)
Ending Balance	(782,125)	(827,445)	(782,125)	(827,445)
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(15,703)	(15,171)	(16,073)	(15,723)
Total other comprehensive income	178	303	548	855
Ending Balance	$ (15,525)	$ (14,868)	$ (15,525)	$ (14,868)